お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、腫瘍薬の世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に腫瘍薬市場を分類しています。
本レポートでは世界の腫瘍薬市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Roche、Celgene、Novartis、Bristol-Myers Squibb、Johnson & Johnson、Merck & Co.、AstraZeneca、Pfizer、Amgen、Eli Lilly、AbbVie、Takeda、Astellas、Ipsen、Sanofi、Bayer、Biogen Idec、Teva、Otsuka、Eisai、Merck KGaA、Gilead Sciences

レポートは腫瘍薬の主要生産者を調査し、主要地域や国の消費状況も提供します。腫瘍薬の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Chemotherapy
    Targeted Therapy
    Immunotherapy (Biologic Therapy)
    Hormonal Therapy
    Others

用途別の市場セグメント：
    Blood Cancer
    Breast Cancer
    Gastrointestinal Cancer
    Prostate Cancer
    Respiratory or Lung Cancer
    Others

本レポートの詳細内容
本レポートは、世界の腫瘍薬市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて腫瘍薬市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）の腫瘍薬生産量、成長率、市場シェアを調査している。

二. 消費面では、腫瘍薬の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーの腫瘍薬売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界の腫瘍薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本腫瘍薬のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：腫瘍薬のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： 腫瘍薬の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおける腫瘍薬の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章腫瘍薬メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：腫瘍薬の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：腫瘍薬の主要メーカーの概要を提供し、製品の説明と仕様、腫瘍薬の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：腫瘍薬の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
Market Analysis and Insights: Global Oncology Drugs Market
The global Oncology Drugs market is projected to grow from US$ 219500 million in 2024 to US$ 395270 million by 2030, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period.
The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.
Report Covers:
This report presents an overview of global market for Oncology Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Oncology Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Oncology Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncology Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Oncology Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Oncology Drugs revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
    Roche
    Celgene
    Novartis
    Bristol-Myers Squibb
    Johnson & Johnson
    Merck & Co.
    AstraZeneca
    Pfizer
    Amgen
    Eli Lilly
    AbbVie
    Takeda
    Astellas
    Ipsen
    Sanofi
    Bayer
    Biogen Idec
    Teva
    Otsuka
    Eisai
    Merck KGaA
    Gilead Sciences

Segment by Type
    Chemotherapy
    Targeted Therapy
    Immunotherapy (Biologic Therapy)
    Hormonal Therapy
    Others

Segment by Application
    Blood Cancer
    Breast Cancer
    Gastrointestinal Cancer
    Prostate Cancer
    Respiratory or Lung Cancer
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Oncology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Chemotherapy
    Table 3. Key Players of Targeted Therapy
    Table 4. Key Players of Immunotherapy (Biologic Therapy)
    Table 5. Key Players of Hormonal Therapy
    Table 6. Key Players of Others
    Table 7. Global Oncology Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 8. Global Oncology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Oncology Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Oncology Drugs Market Share by Region (2019-2024)
    Table 11. Global Oncology Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Oncology Drugs Market Share by Region (2025-2030)
    Table 13. Oncology Drugs Market Trends
    Table 14. Oncology Drugs Market Drivers
    Table 15. Oncology Drugs Market Challenges
    Table 16. Oncology Drugs Market Restraints
    Table 17. Global Oncology Drugs Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Oncology Drugs Revenue Share by Players (2019-2024)
    Table 19. Global Top Oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2023)
    Table 20. Global Oncology Drugs Industry Ranking 2022 VS 2023 VS 2024
    Table 21. Global 5 Largest Players Market Share by Oncology Drugs Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Global Key Players of Oncology Drugs, Headquarters and Area Served
    Table 23. Global Key Players of Oncology Drugs, Product and Application
    Table 24. Global Key Players of Oncology Drugs, Product and Application
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Oncology Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Oncology Drugs Revenue Market Share by Type (2019-2024)
    Table 28. Global Oncology Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Oncology Drugs Revenue Market Share by Type (2025-2030)
    Table 30. Global Oncology Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Oncology Drugs Revenue Share by Application (2019-2024)
    Table 32. Global Oncology Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Oncology Drugs Revenue Share by Application (2025-2030)
    Table 34. North America Oncology Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 35. North America Oncology Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 36. North America Oncology Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 37. North America Oncology Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 38. North America Oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 39. North America Oncology Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 40. North America Oncology Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 41. Europe Oncology Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 42. Europe Oncology Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 43. Europe Oncology Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 44. Europe Oncology Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 45. Europe Oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Europe Oncology Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Europe Oncology Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 48. China Oncology Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 49. China Oncology Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 50. China Oncology Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 51. China Oncology Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 52. Asia Oncology Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 53. Asia Oncology Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 54. Asia Oncology Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 55. Asia Oncology Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 56. Asia Oncology Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 57. Asia Oncology Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 58. Asia Oncology Drugs Market Size by Region (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Oncology Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Oncology Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Oncology Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Oncology Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Oncology Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 64. Middle East, Africa, and Latin America Oncology Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 65. Middle East, Africa, and Latin America Oncology Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 66. Roche Company Details
    Table 67. Roche Business Overview
    Table 68. Roche Oncology Drugs Product
    Table 69. Roche Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 70. Roche Recent Developments
    Table 71. Celgene Company Details
    Table 72. Celgene Business Overview
    Table 73. Celgene Oncology Drugs Product
    Table 74. Celgene Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 75. Celgene Recent Developments
    Table 76. Novartis Company Details
    Table 77. Novartis Business Overview
    Table 78. Novartis Oncology Drugs Product
    Table 79. Novartis Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 80. Novartis Recent Developments
    Table 81. Bristol-Myers Squibb Company Details
    Table 82. Bristol-Myers Squibb Business Overview
    Table 83. Bristol-Myers Squibb Oncology Drugs Product
    Table 84. Bristol-Myers Squibb Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 85. Bristol-Myers Squibb Recent Developments
    Table 86. Johnson & Johnson Company Details
    Table 87. Johnson & Johnson Business Overview
    Table 88. Johnson & Johnson Oncology Drugs Product
    Table 89. Johnson & Johnson Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 90. Johnson & Johnson Recent Developments
    Table 91. Merck & Co. Company Details
    Table 92. Merck & Co. Business Overview
    Table 93. Merck & Co. Oncology Drugs Product
    Table 94. Merck & Co. Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 95. Merck & Co. Recent Developments
    Table 96. AstraZeneca Company Details
    Table 97. AstraZeneca Business Overview
    Table 98. AstraZeneca Oncology Drugs Product
    Table 99. AstraZeneca Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 100. AstraZeneca Recent Developments
    Table 101. Pfizer Company Details
    Table 102. Pfizer Business Overview
    Table 103. Pfizer Oncology Drugs Product
    Table 104. Pfizer Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 105. Pfizer Recent Developments
    Table 106. Amgen Company Details
    Table 107. Amgen Business Overview
    Table 108. Amgen Oncology Drugs Product
    Table 109. Amgen Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 110. Amgen Recent Developments
    Table 111. Eli Lilly Company Details
    Table 112. Eli Lilly Business Overview
    Table 113. Eli Lilly Oncology Drugs Product
    Table 114. Eli Lilly Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 115. Eli Lilly Recent Developments
    Table 116. AbbVie Company Details
    Table 117. AbbVie Business Overview
    Table 118. AbbVie Oncology Drugs Product
    Table 119. AbbVie Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 120. AbbVie Recent Developments
    Table 121. Takeda Company Details
    Table 122. Takeda Business Overview
    Table 123. Takeda Oncology Drugs Product
    Table 124. Takeda Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 125. Takeda Recent Developments
    Table 126. Astellas Company Details
    Table 127. Astellas Business Overview
    Table 128. Astellas Oncology Drugs Product
    Table 129. Astellas Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 130. Astellas Recent Developments
    Table 131. Ipsen Company Details
    Table 132. Ipsen Business Overview
    Table 133. Ipsen Oncology Drugs Product
    Table 134. Ipsen Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 135. Ipsen Recent Developments
    Table 136. Sanofi Company Details
    Table 137. Sanofi Business Overview
    Table 138. Sanofi Oncology Drugs Product
    Table 139. Sanofi Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 140. Sanofi Recent Developments
    Table 141. Bayer Company Details
    Table 142. Bayer Business Overview
    Table 143. Bayer Oncology Drugs Product
    Table 144. Bayer Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 145. Bayer Recent Developments
    Table 146. Biogen Idec Company Details
    Table 147. Biogen Idec Business Overview
    Table 148. Biogen Idec Oncology Drugs Product
    Table 149. Biogen Idec Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 150. Biogen Idec Recent Developments
    Table 151. Teva Company Details
    Table 152. Teva Business Overview
    Table 153. Teva Oncology Drugs Product
    Table 154. Teva Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 155. Teva Recent Developments
    Table 156. Otsuka Company Details
    Table 157. Otsuka Business Overview
    Table 158. Otsuka Oncology Drugs Product
    Table 159. Otsuka Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 160. Otsuka Recent Developments
    Table 161. Eisai Company Details
    Table 162. Eisai Business Overview
    Table 163. Eisai Oncology Drugs Product
    Table 164. Eisai Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 165. Eisai Recent Developments
    Table 166. Merck KGaA Company Details
    Table 167. Merck KGaA Business Overview
    Table 168. Merck KGaA Oncology Drugs Product
    Table 169. Merck KGaA Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 170. Merck KGaA Recent Developments
    Table 171. Gilead Sciences Company Details
    Table 172. Gilead Sciences Business Overview
    Table 173. Gilead Sciences Oncology Drugs Product
    Table 174. Gilead Sciences Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)
    Table 175. Gilead Sciences Recent Developments
    Table 176. Research Programs/Design for This Report
    Table 177. Key Data Information from Secondary Sources
    Table 178. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Oncology Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Oncology Drugs Market Share by Type: 2023 VS 2030
    Figure 3. Chemotherapy Features
    Figure 4. Targeted Therapy Features
    Figure 5. Immunotherapy (Biologic Therapy) Features
    Figure 6. Hormonal Therapy Features
    Figure 7. Others Features
    Figure 8. Global Oncology Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 9. Global Oncology Drugs Market Share by Application: 2023 VS 2030
    Figure 10. Blood Cancer Case Studies
    Figure 11. Breast Cancer Case Studies
    Figure 12. Gastrointestinal Cancer Case Studies
    Figure 13. Prostate Cancer Case Studies
    Figure 14. Respiratory or Lung Cancer Case Studies
    Figure 15. Others Case Studies
    Figure 16. Oncology Drugs Report Years Considered
    Figure 17. Global Oncology Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 18. Global Oncology Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 19. Global Oncology Drugs Market Share by Region: 2023 VS 2030
    Figure 20. Global Oncology Drugs Market Share by Players in 2023
    Figure 21. Global Top Oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2023)
    Figure 22. The Top 10 and 5 Players Market Share by Oncology Drugs Revenue in 2023
    Figure 23. North America Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. North America Oncology Drugs Market Share by Type (2019-2030)
    Figure 25. North America Oncology Drugs Market Share by Application (2019-2030)
    Figure 26. North America Oncology Drugs Market Share by Country (2019-2030)
    Figure 27. United States Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Canada Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Europe Oncology Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 30. Europe Oncology Drugs Market Share by Type (2019-2030)
    Figure 31. Europe Oncology Drugs Market Share by Application (2019-2030)
    Figure 32. Europe Oncology Drugs Market Share by Country (2019-2030)
    Figure 33. Germany Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. France Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. U.K. Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Italy Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Russia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Nordic Countries Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. China Oncology Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 40. China Oncology Drugs Market Share by Type (2019-2030)
    Figure 41. China Oncology Drugs Market Share by Application (2019-2030)
    Figure 42. Asia Oncology Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 43. Asia Oncology Drugs Market Share by Type (2019-2030)
    Figure 44. Asia Oncology Drugs Market Share by Application (2019-2030)
    Figure 45. Asia Oncology Drugs Market Share by Region (2019-2030)
    Figure 46. Japan Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. South Korea Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. China Taiwan Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Southeast Asia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. India Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Australia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Middle East, Africa, and Latin America Oncology Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 53. Middle East, Africa, and Latin America Oncology Drugs Market Share by Type (2019-2030)
    Figure 54. Middle East, Africa, and Latin America Oncology Drugs Market Share by Application (2019-2030)
    Figure 55. Middle East, Africa, and Latin America Oncology Drugs Market Share by Country (2019-2030)
    Figure 56. Brazil Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Mexico Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Turkey Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Saudi Arabia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Israel Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 61. GCC Countries Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 62. Roche Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 63. Celgene Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 64. Novartis Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 66. Johnson & Johnson Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 67. Merck & Co. Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 68. AstraZeneca Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 69. Pfizer Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 70. Amgen Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 71. Eli Lilly Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 72. AbbVie Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 73. Takeda Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 74. Astellas Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 75. Ipsen Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 76. Sanofi Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 77. Bayer Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 78. Biogen Idec Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 79. Teva Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 80. Otsuka Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 81. Eisai Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 82. Merck KGaA Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 83. Gilead Sciences Revenue Growth Rate in Oncology Drugs Business (2019-2024)
    Figure 84. Bottom-up and Top-down Approaches for This Report
    Figure 85. Data Triangulation
    Figure 86. Key Executives Interviewed